Exonate Overview

  • Founded
  • 2013
Founded
  • Status
  • Private
  • Employees
  • 11
Employees
  • Latest Deal Type
  • Early Stage VC
  • Latest Deal Amount
  • $2.17M
Latest Deal Amount
  • Investors
  • 13

Exonate General Information

Description

Developer of small molecule drugs designed to modulate alternative mRNA splicing to address diseases of high unmet medical need. The company's lead program molecules, for wet Age-Related Macular Degeneration (wet AMD), act via a novel mechanism of action to inhibit pathological blood vessel and reduces the formation of pathological VEGF (Vascular Endothelial Growth Factor) without inhibiting beneficial, non-pathological VEGF, enabling doctors to improve the treatment of patients with retinal vascular diseases and to transform the lives of those suffering from vision loss.

Contact Information

Website
www.exonate.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Primary Office
  • WTL Moorfield Road
  • Duxford
  • Cambridge CB22 4PS
  • England, United Kingdom
+44 01223 000000

Exonate Timeline

2017201820192020
Financing Round
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Exonate Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Early Stage VC 12-Sep-2018 $2.17M 00.000 00.000 Completed Clinical Trials - General
4. Grant 06-Feb-2017 00.000 00.000 Completed Clinical Trials - General
3. Early Stage VC 01-Dec-2016 00.00 00.000 00.000 Completed Startup
2. Early Stage VC 05-Oct-2015 $1.21M $1.87M 00.000 Completed Startup
1. Seed Round 01-Mar-2014 $651K $651K 00.000 Completed Startup
To view Exonate’s complete valuation and funding history, request access »

Exonate Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Ordinary 00,000 00.000000 0000.00 0000.00 00 0000.00 00.000
Ordinary 00,000 00.000000 000.00 000.00 00 000.00 00.000
Ordinary 14,141 $0.012877 $72.11 $72.11 1x $72.11 17.79%
Ordinary 7,860 $0.012877 $64.39 $64.39 1x $64.39 9.89%
To view Exonate’s complete cap table history, request access »

Exonate Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of small molecule drugs designed to modulate alternative mRNA splicing to address diseases of high unmet medic
Drug Discovery
Cambridge, United Kingdom
11 As of 2016
00.000
0.000 0000-00-00
0000000000 0 00.000

00000000

re et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi u
0000 000000000
Charlottesville, VA
0 As of 0000
000.00
0000000000 0 000.00

000 0000

didunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco
0000 000000000
Ann Arbor, MI
00 As of 0000
000.00
0000000000 0 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Exonate Competitors (14)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
TearSolutions Venture Capital-Backed Charlottesville, VA 0 000.00 0000000000 0 000.00
000 000000000000 Venture Capital-Backed Ann Arbor, MI 00 000.00 0000000000 0 000.00
0000000 Formerly VC-backed Jena, Germany 00 00000 000000 - 000 00000
000000 00000000 Formerly VC-backed Palo Alto, CA 00 00000 00000000 00000
00000 Formerly PE-Backed Thousand Oaks, CA 00000 00.000 000000000000 00.000
You’re viewing 5 of 14 competitors. Get the full list »

Exonate Executive Team (6)

Name Title Board Seat Contact Info
Catherine Beech MD Chief Executive Officer & Board Member
Loic Lhuillier Ph.D Chief Operating Officer
David Bates Ph.D Co-Founder, Chief Scientific Officer & Board Member
Christopher O'Connor Financial Controller
Steven Harper Medical Director & Board Member
You’re viewing 5 of 6 executive team members. Get the full list »

Exonate Board Members (8)

Name Representing Role Since
Andrew Naylor Ph.D Self Board Member 000 0000
Catherine Beech MD Exonate Chief Executive Officer & Board Member 000 0000
Christopher Torrance Ph.D Self Board Member 000 0000
David Bates Ph.D Exonate Co-Founder, Chief Scientific Officer & Board Member 000 0000
John Kurek Ph.D Uniseed Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »

Exonate Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Exonate Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
R42 Group Venture Capital Minority 000 0000 000000 0
Wellcome Trust Limited Partner 000 0000 000000 0
Martlet Venture Capital Minority 000 0000 000000 0
O2h Ventures Venture Capital Minority 000 0000 000000 0
Parkwalk Advisors Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 13 investors. Get the full list »

Ready to get started?

Request a free trial